Document is current
Any future updates will be listed below
-
Authors
Gabor, Leonie
Zalghout, Sara
Martinod, Kimberly https://orcid.org/0000-0002-1026-6107
Maurer, Christoph J. https://orcid.org/0000-0002-0305-0797
Kremmer, Roxana
Culmann, Elisabeth
Feisst, Manuel https://orcid.org/0000-0002-5016-9731
Schneider, Hauke https://orcid.org/0000-0002-9641-0922
-
Clinical Trials BETA
Clinical trials referenced in this document:
drks00025118 at German Clinical Trials RegisterDocuments that mention this clinical trial
Neutrophil Extracellular Traps in Patients with Intracerebral Hemorrhage
https://doi.org/10.1007/s12028-026-02577-1
-
Funding
Funding for this research was provided by:
University of Augsburg (2023-8660015)
Universitätsklinikum Augsburg
- License Information
-
More Information
Article History
Received: 1 March 2026
Accepted: 3 June 2026
First Online: 6 July 2026
Conflicts of Interest
: Dr. Martinod has received consulting fees from PEEL Therapeutics. She is an inventor on granted US patent US10617742B2 for the methods for treating and preventing neutrophil-derived NET toxicity and thrombosis and granted US patent US11426405B2 on JAK–STAT signaling inhibition preventing NET formation. All other authors declare that they have no conflict of interest.
: Institutional review board approval was obtained from the Ethics Committee of the Bavarian Medical Association before enrollment of patients (BLÄK, EK 22098). Written informed consent for study participation was provided by each patient or their legally authorized representative. Conditional inclusion was possible for patients who were not able to consent initially. Consent was waived for patients who were not able to consent initially and who died during hospital stay.
: DRKS00025118, German Clinical Trials Register, .
: The authors declare that no AI-assisted technologies were used in the production of the submitted work.
